Cardiovascular manifestations in duchenne/becker muscular dystrophy and other primary myopathies

Douglas A. Stoller, Pradeep P.A. Mammen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Patients with muscular dystrophy face a lifetime of physical challenges due to their neuromuscular disease. Physical challenges are faced on a daily basis, and as such this is the initial focus from a clinical perspective. Over the past decades, improvements in physical and respiratory therapy, coupled with advances in technology, have substantially improved quality of life for this patient group. Improvements in computer technology such as voice recognition have increased access to education and allowed greater independence for muscular dystrophy patients. Use of assisted cough techniques and ventilatory support, particularly non-invasive support, has significantly prolonged the lifespan of patients with neuromuscular disease, particularly Duchenne muscular dystrophy. As a result, cardiac disease is now thought to be the leading cause of death among those with Duchenne muscular dystrophy, and represents a new medical challenge for the current generation of patients. Because skeletal and cardiac muscle share a common embryologic origin, the underlying genetic mutations generally impact both skeletal and cardiac muscle. Cardiac disease is common among patients with neuromuscular disease. Essentially all men with Duchenne muscular dystrophy will develop cardiomyopathy by age 18. In contrast, cardiac involvement in other muscular dystrophy patients depends on the specific subtype. For example, LGMD1B patients commonly have arrhythmias and cardiomyopathy while LGMD1C patients have isolated cases of hypertrophic cardiomyopathy. Patients with Becker muscular dystrophy exhibit a broad range of cardiac phenotype-from patients with no cardiac involvement to those with severe cardiomyopathy requiring heart transplant. Yet while cardiac disease is common, its scope and impact in neuromuscular patients is under recognized. Neurology clinics dedicated to muscular dystrophy are common, while only a handful of dedicated neuromuscular cardiomyopathy clinics exist (primarily at academic centers). Fewer still receive active treatment for cardiac disease. In this chapter, we begin with a concise review of the basic assessment and workup of congestive heart failure in the general adult population. With this as a backdrop, the cardiac management of three common neuromuscular diseases- the dystrophinopathies, Limb-Girdle muscular dystrophy, and congenital muscular dystrophy.

Original languageEnglish (US)
Title of host publicationCardiovascular Genetics and Genomics
Subtitle of host publicationPrinciples and Clinical Practice
PublisherSpringer International Publishing
Pages523-543
Number of pages21
ISBN (Electronic)9783319661148
ISBN (Print)9783319661124
DOIs
StatePublished - Jan 17 2018

Fingerprint

Duchenne Muscular Dystrophy
Muscular Diseases
Muscular Dystrophies
Neuromuscular Diseases
Cardiomyopathies
Heart Diseases
Respiratory therapy
Muscle
Physical therapy
Transplants
Myocardium
Neurology
Skeletal Muscle
Speech recognition
Limb-Girdle Muscular Dystrophies
Technology
Respiratory Therapy
Education
Hypertrophic Cardiomyopathy
Cough

Keywords

  • Adult cardiomyopathy
  • Becker muscular dystrophy
  • Congenital muscular dystrophy
  • Duchenne muscular dystrophy
  • Limb-Girdle muscular dystrophy

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Stoller, D. A., & Mammen, P. P. A. (2018). Cardiovascular manifestations in duchenne/becker muscular dystrophy and other primary myopathies. In Cardiovascular Genetics and Genomics: Principles and Clinical Practice (pp. 523-543). Springer International Publishing. https://doi.org/10.1007/978-3-319-66114-8_16

Cardiovascular manifestations in duchenne/becker muscular dystrophy and other primary myopathies. / Stoller, Douglas A.; Mammen, Pradeep P.A.

Cardiovascular Genetics and Genomics: Principles and Clinical Practice. Springer International Publishing, 2018. p. 523-543.

Research output: Chapter in Book/Report/Conference proceedingChapter

Stoller, DA & Mammen, PPA 2018, Cardiovascular manifestations in duchenne/becker muscular dystrophy and other primary myopathies. in Cardiovascular Genetics and Genomics: Principles and Clinical Practice. Springer International Publishing, pp. 523-543. https://doi.org/10.1007/978-3-319-66114-8_16
Stoller DA, Mammen PPA. Cardiovascular manifestations in duchenne/becker muscular dystrophy and other primary myopathies. In Cardiovascular Genetics and Genomics: Principles and Clinical Practice. Springer International Publishing. 2018. p. 523-543 https://doi.org/10.1007/978-3-319-66114-8_16
Stoller, Douglas A. ; Mammen, Pradeep P.A. / Cardiovascular manifestations in duchenne/becker muscular dystrophy and other primary myopathies. Cardiovascular Genetics and Genomics: Principles and Clinical Practice. Springer International Publishing, 2018. pp. 523-543
@inbook{f355091457f140e6993b650e8855a8d6,
title = "Cardiovascular manifestations in duchenne/becker muscular dystrophy and other primary myopathies",
abstract = "Patients with muscular dystrophy face a lifetime of physical challenges due to their neuromuscular disease. Physical challenges are faced on a daily basis, and as such this is the initial focus from a clinical perspective. Over the past decades, improvements in physical and respiratory therapy, coupled with advances in technology, have substantially improved quality of life for this patient group. Improvements in computer technology such as voice recognition have increased access to education and allowed greater independence for muscular dystrophy patients. Use of assisted cough techniques and ventilatory support, particularly non-invasive support, has significantly prolonged the lifespan of patients with neuromuscular disease, particularly Duchenne muscular dystrophy. As a result, cardiac disease is now thought to be the leading cause of death among those with Duchenne muscular dystrophy, and represents a new medical challenge for the current generation of patients. Because skeletal and cardiac muscle share a common embryologic origin, the underlying genetic mutations generally impact both skeletal and cardiac muscle. Cardiac disease is common among patients with neuromuscular disease. Essentially all men with Duchenne muscular dystrophy will develop cardiomyopathy by age 18. In contrast, cardiac involvement in other muscular dystrophy patients depends on the specific subtype. For example, LGMD1B patients commonly have arrhythmias and cardiomyopathy while LGMD1C patients have isolated cases of hypertrophic cardiomyopathy. Patients with Becker muscular dystrophy exhibit a broad range of cardiac phenotype-from patients with no cardiac involvement to those with severe cardiomyopathy requiring heart transplant. Yet while cardiac disease is common, its scope and impact in neuromuscular patients is under recognized. Neurology clinics dedicated to muscular dystrophy are common, while only a handful of dedicated neuromuscular cardiomyopathy clinics exist (primarily at academic centers). Fewer still receive active treatment for cardiac disease. In this chapter, we begin with a concise review of the basic assessment and workup of congestive heart failure in the general adult population. With this as a backdrop, the cardiac management of three common neuromuscular diseases- the dystrophinopathies, Limb-Girdle muscular dystrophy, and congenital muscular dystrophy.",
keywords = "Adult cardiomyopathy, Becker muscular dystrophy, Congenital muscular dystrophy, Duchenne muscular dystrophy, Limb-Girdle muscular dystrophy",
author = "Stoller, {Douglas A.} and Mammen, {Pradeep P.A.}",
year = "2018",
month = "1",
day = "17",
doi = "10.1007/978-3-319-66114-8_16",
language = "English (US)",
isbn = "9783319661124",
pages = "523--543",
booktitle = "Cardiovascular Genetics and Genomics",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Cardiovascular manifestations in duchenne/becker muscular dystrophy and other primary myopathies

AU - Stoller, Douglas A.

AU - Mammen, Pradeep P.A.

PY - 2018/1/17

Y1 - 2018/1/17

N2 - Patients with muscular dystrophy face a lifetime of physical challenges due to their neuromuscular disease. Physical challenges are faced on a daily basis, and as such this is the initial focus from a clinical perspective. Over the past decades, improvements in physical and respiratory therapy, coupled with advances in technology, have substantially improved quality of life for this patient group. Improvements in computer technology such as voice recognition have increased access to education and allowed greater independence for muscular dystrophy patients. Use of assisted cough techniques and ventilatory support, particularly non-invasive support, has significantly prolonged the lifespan of patients with neuromuscular disease, particularly Duchenne muscular dystrophy. As a result, cardiac disease is now thought to be the leading cause of death among those with Duchenne muscular dystrophy, and represents a new medical challenge for the current generation of patients. Because skeletal and cardiac muscle share a common embryologic origin, the underlying genetic mutations generally impact both skeletal and cardiac muscle. Cardiac disease is common among patients with neuromuscular disease. Essentially all men with Duchenne muscular dystrophy will develop cardiomyopathy by age 18. In contrast, cardiac involvement in other muscular dystrophy patients depends on the specific subtype. For example, LGMD1B patients commonly have arrhythmias and cardiomyopathy while LGMD1C patients have isolated cases of hypertrophic cardiomyopathy. Patients with Becker muscular dystrophy exhibit a broad range of cardiac phenotype-from patients with no cardiac involvement to those with severe cardiomyopathy requiring heart transplant. Yet while cardiac disease is common, its scope and impact in neuromuscular patients is under recognized. Neurology clinics dedicated to muscular dystrophy are common, while only a handful of dedicated neuromuscular cardiomyopathy clinics exist (primarily at academic centers). Fewer still receive active treatment for cardiac disease. In this chapter, we begin with a concise review of the basic assessment and workup of congestive heart failure in the general adult population. With this as a backdrop, the cardiac management of three common neuromuscular diseases- the dystrophinopathies, Limb-Girdle muscular dystrophy, and congenital muscular dystrophy.

AB - Patients with muscular dystrophy face a lifetime of physical challenges due to their neuromuscular disease. Physical challenges are faced on a daily basis, and as such this is the initial focus from a clinical perspective. Over the past decades, improvements in physical and respiratory therapy, coupled with advances in technology, have substantially improved quality of life for this patient group. Improvements in computer technology such as voice recognition have increased access to education and allowed greater independence for muscular dystrophy patients. Use of assisted cough techniques and ventilatory support, particularly non-invasive support, has significantly prolonged the lifespan of patients with neuromuscular disease, particularly Duchenne muscular dystrophy. As a result, cardiac disease is now thought to be the leading cause of death among those with Duchenne muscular dystrophy, and represents a new medical challenge for the current generation of patients. Because skeletal and cardiac muscle share a common embryologic origin, the underlying genetic mutations generally impact both skeletal and cardiac muscle. Cardiac disease is common among patients with neuromuscular disease. Essentially all men with Duchenne muscular dystrophy will develop cardiomyopathy by age 18. In contrast, cardiac involvement in other muscular dystrophy patients depends on the specific subtype. For example, LGMD1B patients commonly have arrhythmias and cardiomyopathy while LGMD1C patients have isolated cases of hypertrophic cardiomyopathy. Patients with Becker muscular dystrophy exhibit a broad range of cardiac phenotype-from patients with no cardiac involvement to those with severe cardiomyopathy requiring heart transplant. Yet while cardiac disease is common, its scope and impact in neuromuscular patients is under recognized. Neurology clinics dedicated to muscular dystrophy are common, while only a handful of dedicated neuromuscular cardiomyopathy clinics exist (primarily at academic centers). Fewer still receive active treatment for cardiac disease. In this chapter, we begin with a concise review of the basic assessment and workup of congestive heart failure in the general adult population. With this as a backdrop, the cardiac management of three common neuromuscular diseases- the dystrophinopathies, Limb-Girdle muscular dystrophy, and congenital muscular dystrophy.

KW - Adult cardiomyopathy

KW - Becker muscular dystrophy

KW - Congenital muscular dystrophy

KW - Duchenne muscular dystrophy

KW - Limb-Girdle muscular dystrophy

UR - http://www.scopus.com/inward/record.url?scp=85046164088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046164088&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-66114-8_16

DO - 10.1007/978-3-319-66114-8_16

M3 - Chapter

AN - SCOPUS:85046164088

SN - 9783319661124

SP - 523

EP - 543

BT - Cardiovascular Genetics and Genomics

PB - Springer International Publishing

ER -